| Identification of a novel human islet amyloid polypeptide β-sheet domain and factors influencing fibrillogenesis ETAS Jaikaran, CE Higham, LC Serpell, J Zurdo, M Gross, A Clark, ... Journal of molecular biology 308 (3), 515-525, 2001 | 294 | 2001 |
| Hypopituitarism CE Higham, G Johannsson, SM Shalet The Lancet 388 (10058), 2403-2415, 2016 | 256 | 2016 |
| GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults DB Allen, P Backeljauw, M Bidlingmaier, BMK Biller, M Boguszewski, ... European Journal of Endocrinology 174 (2), P1-P9, 2016 | 236 | 2016 |
| Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort J Dénes, F Swords, E Rattenberry, K Stals, M Owens, T Cranston, ... The Journal of Clinical Endocrinology & Metabolism 100 (3), E531-E541, 2015 | 179 | 2015 |
| Preparation of synthetic human islet amyloid polypeptide (IAPP) in a stable conformation to enable study of conversion to amyloid‐like fibrils CE Higham, ETAS Jaikaran, PE Fraser, M Gross, A Clark FEBS letters 470 (1), 55-60, 2000 | 144 | 2000 |
| SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy CE Higham, A Olsson-Brown, P Carroll, T Cooksley, J Larkin, P Lorigan, ... Endocrine connections 7 (7), G1-G7, 2018 | 136 | 2018 |
| Long-term endocrine and metabolic consequences of cancer treatment: a systematic review J Gebauer, C Higham, T Langer, C Denzer, G Brabant Endocrine Reviews 40 (3), 711-767, 2019 | 129 | 2019 |
| The antimalarial agent mefloquine inhibits ATP-sensitive K-channels FM Gribble, TME Davis, CE Higham, A Clark, FM Ashcroft British journal of pharmacology 131 (4), 756, 2000 | 114 | 2000 |
| Hyponatraemia secondary to nivolumab-induced primary adrenal failure H Trainer, P Hulse, CE Higham, P Trainer, P Lorigan Endocrinology, diabetes & metabolism case reports 2016 (1), 2016 | 113 | 2016 |
| Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial CE Higham, AB Atkinson, S Aylwin, M Bidlingmaier, WM Drake, A Lewis, ... The Journal of Clinical Endocrinology & Metabolism 97 (4), 1187-1193, 2012 | 111 | 2012 |
| Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group A Roberts, J James, K Dhatariya, ... Diabetic Medicine 35 (8), 1011-1017, 2018 | 105 | 2018 |
| Association between hepatic steatosis and serum IGF1 and IGFBP-3 levels in a population-based sample H Völzke, M Nauck, R Rettig, M Dörr, C Higham, G Brabant, ... European Journal of Endocrinology 161 (5), 705-713, 2009 | 99 | 2009 |
| 60 years of neuroendocrinology: the hypothalamo-GH axis: the past 60 years PG Murray, CE Higham, PE Clayton Journal of Endocrinology 226 (2), T123-T140, 2015 | 88 | 2015 |
| Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves' hyperthyroidism: a phase I study SHS Pearce, C Dayan, DC Wraith, K Barrell, N Olive, L Jansson, ... Thyroid 29 (7), 1003-1011, 2019 | 86 | 2019 |
| Acromegaly surgery in Manchester revisited–the impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission YY Wang, C Higham, T Kearney, JRE Davis, P Trainer, KK Gnanalingham Clinical endocrinology 76 (3), 399-406, 2012 | 85 | 2012 |
| Formation of amyloid fibrils by peptides derived from the bacterial cold shock protein CspB M Groß, DK Wilkins, MC Pitkeathly, EW Chung, C Higham, A Clark, ... Protein Science 8 (6), 1350-1357, 1999 | 84 | 1999 |
| Processing of synthetic pro‐islet amyloid polypeptide (proIAPP) ‘amylin’ by recombinant prohormone convertase enzymes, PC2 and PC3, in vitro CE Higham, RL Hull, L Lawrie, KIJ Shennan, JF Morris, NP Birch, ... European Journal of Biochemistry 267 (16), 4998-5004, 2000 | 81 | 2000 |
| Long‐term experience of pegvisomant therapy as a treatment for acromegaly CE Higham, TT Chung, J Lawrance, WM Drake, PJ Trainer Clinical endocrinology 71 (1), 86-91, 2009 | 79 | 2009 |
| Supportive care: an indispensable component of modern oncology R Berman, A Davies, T Cooksley, R Gralla, L Carter, E Darlington, ... Clinical Oncology 32 (11), 781-788, 2020 | 77 | 2020 |
| Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly CE Higham, S Rowles, D Russell-Jones, AM Umpleby, PJ Trainer The Journal of Clinical Endocrinology & Metabolism 94 (7), 2459-2463, 2009 | 67 | 2009 |
